Medtronic (MDT)
NYSEHealth CareMedical DevicesSnapshot 2026-07-07
$83.84+0.94%
Close 2026-07-07 · 1-day change
Reading MDT? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track MDT free→NYSEHealth CareMedical DevicesSnapshot 2026-07-07
Reading MDT? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track MDT free→Medtronic grows sales about 7% a year. Key franchises like Cardiac Ablation grew 78% last quarter. Profit per share should rise to about $6 next year. The company raised its dividend for 49 years in a row.
Cyberattacks and tariffs could raise costs and hurt profits. Sales growth may slow below 5%. Profit per share might fall under $5.60 next year.
The price is about 5% below our fair value near $88. Analysts expect 5.5% revenue growth. Our fair value is 7% below the Street median of $95.
Breaks if: Dividend per share does not increase in FY26
Continue increasing quarterly dividends annually, marking 49 consecutive years of dividend increases.
Stated as a priority in 2 of last 5 quarters. The company increased its quarterly dividend from $0.71 in Q1 FY26 to $0.72 in Q1 FY27, marking 49 consecutive years of dividend increases. This demonstrates consistent capital return focus with incremental increases.
Breaks if: Cardiac Ablation growth falls below 6% in Q4 FY26
Focus on accelerating growth in Cardiac Ablation Solutions, Neuromodulation, Structural Heart, Diabetes, and Surgical Robotics.
Stated as a priority in 5 of last 5 quarters. Cardiac Ablation Solutions revenue grew sharply, up 78% in Q4 FY26 versus prior year. Neuromodulation and Diabetes also showed strong growth, with 7.0% and 15.0% increases respectively in Q4. Management consistently highlights these franchises and new products as growth drivers, showing delivering momentum.
Breaks if: EPS falls below $5.60 in FY27
Sustain and improve non-GAAP diluted EPS with operational efficiencies and growth investments, raising FY26 and FY27 EPS guidance.
Stated as a priority in 5 of last 5 quarters. FY26 non-GAAP diluted EPS grew modestly from $5.49 in FY25 to $5.53 in FY26. Management raised FY26 EPS guidance multiple times, ending at $5.62-$5.66, and guides FY27 EPS growth of 6.7%-8.5% to $5.90-$6.00. The trajectory shows steady delivery with raised expectations.
Breaks if: organic revenue growth falls below 5% in FY27
Continue delivering mid-single digit organic revenue growth with acceleration in key franchises and new product launches.
Stated as a priority in 5 of last 5 quarters. FY26 organic revenue grew 5.8% from 4.9% in FY25, with quarterly organic growth ranging from 4.8% to 6.0%. Management guides FY27 organic revenue growth to 6.75%-7.25%, indicating acceleration. The trajectory is delivering consistent growth and upward momentum.
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Dividend for Q1 FY27 increased to $0.72 per share; 49th consecutive year of dividend increases.”
“Dividend for Q1 FY26 increased to $0.71 per share; 48th consecutive year of dividend increases.”
“Cardiac Ablation Solutions revenue increased 78% globally, including 124% U.S. growth.”
“Cardiac Ablation Solutions revenue increased 80%, including 137% in the U.S.”
“Cardiac Ablation Solutions revenue increased 71%, including 128% in the U.S.”
“Cardiac Ablation Solutions revenue increased nearly 50%, including 72% in the U.S.”
“Cardiac Ablation Solutions Q4 revenue increased nearly 30%; business delivered $1.0 billion in FY25 revenue.”
“FY26 non-GAAP diluted EPS was $5.53, up 0.7% year-over-year.”
“Reiterated FY26 diluted non-GAAP EPS guidance of $5.62 to $5.66.”
“Raised FY26 diluted non-GAAP EPS guidance to $5.62 to $5.66 from prior $5.60 to $5.66.”
“Raised FY26 diluted non-GAAP EPS guidance to $5.60 to $5.66 from prior $5.50 to $5.60.”
“FY25 non-GAAP diluted EPS was $5.49, up 6% year-over-year.”
“FY26 revenue increased 8.4% as reported and 5.8% organic.”
“Q3 revenue increased 8.7% as reported and 6.0% organic.”
“Q2 revenue increased 6.6% as reported and 5.5% organic.”
“Q1 revenue increased 8.4% as reported and 4.8% organic.”
“FY25 revenue increased 3.6% as reported and 4.9% organic.”